Accuracy Assessment of the GlucoMen® Day CGM System in Individuals with Type 1 Diabetes: A Pilot Study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The aim of this study was to evaluate the accuracy and usability of a novel continuous glucose monitoring (CGM) system designed for needle-free insertion and reduced environmental impact. We assessed the sensor performance of two GlucoMen® Day CGM systems worn simultaneously by eight participants with type 1 diabetes. Self-monitoring of blood glucose (SMBG) was performed regularly over 14 days at home. Participants underwent two standardized, 5-h meal challenges at the research center with frequent plasma glucose (PG) measurements using a laboratory reference (YSI) instrument. When comparing CGM to PG, the overall mean absolute relative difference (MARD) was 9.7 [2.6–14.6]%. The overall MARD for CGM vs. SMBG was 13.1 [3.5–18.6]%. The consensus error grid (CEG) analysis showed 98% of both CGM/PG and CGM/SMBG pairs in the clinically acceptable zones A and B. The analysis confirmed that GlucoMen® Day CGM meets the clinical requirements for state-of-the-art CGM. In addition, the needle-free insertion technology is well tolerated by users and reduces medical waste compared to conventional CGM systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, publicly available accuracy data from both observational and randomized clinical trials supporting some non-iCGM-approved entrants include small sample sizes and/or very few data points in the critical range of <70 mg/dL, more stable patients, and no glucose and insulin challenges, and data may not have been published in peer-reviewed journals.8,11,20-24,35,36,39-48”
From Importance of FDA-integrated continuous glucose monitors to ensure accuracy of continuous glucose monitoring (2025) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nonadjunctive CGM provides valuable information on glucose levels and is indicated to replace information obtained from standard BGM, without requiring verification, and to aid daily and long-term DM-related treatment decisions, such as insulin dosing (Table 2).7,15,17-19,24,29,35”
From Importance of FDA-integrated continuous glucose monitors to ensure accuracy of continuous glucose monitoring (2025) · cites this paper as [24]
In the citing paper
“This category of CGM performance specified by the U.S. FDA is the strictest accuracy standard defined by any regulatory agency in the world. 16”
From Importance of FDA-integrated continuous glucose monitors to ensure accuracy of continuous glucose monitoring (2025) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 3×
“Furthermore, as CGM enables easy assessment of the time spent in target range (TIR), which has been shown to be a valid marker of glycemic control alongside HbA1c, there has been an evolution of individual treatment guidelines for CGM use with a focus on TIR [12].”
BackgroundState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“As a result, PLWD using CGM technology show improvement in HbA1c, glucose variability, hypoglycemic events, well-being, treatment satisfaction and less fear of hypoglycemia compared to SMBG [1-3].”
BackgroundValidation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793 · cited 1×
“By mod ling the 7-point glucose profiles coll cted in the DCCT (Diabetes Control and Complications Trial), it was shown that TIR was strongly associated with development of microalbuminuria and retinopathy progression, suggesting that it represents a valid surrogate indicator of microvascular complications [17].”
BackgroundLind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705 · cited 1×
“As a result, PLWD using CGM technology show improvement in HbA1c, glucose variability, hypoglycemic events, well-being, treatment satisfaction and less fear of hypoglycemia compared to SMBG [1-3].”
BackgroundThe Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System
Bailey, T., Bode, B. W., Christiansen, M. P., Klaff, L. J., & Alva, S. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0378 · Cited by 685
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Polonsky, W. H., Hessler, D., Ruedy, K. J., & Beck, R. W. (2017) · Diabetes Care · doi:10.2337/dc17-0133 · Cited by 346
Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry
Wong, J. C., Foster, N. C., Maahs, D. M., Raghinaru, D., Bergenstal, R. M., Ahmann, A. J., Peters, A. L., Bode, B. W., Aleppo, G., Hirsch, I. B., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0303 · Cited by 318
Cited by
Freckmann, G., Eichenlaub, M., Waldenmaier, D., Pleus, S., Wehrstedt, S., Haug, C., Witthauer, L., Jendle, J., Hinzmann, R., Thomas, A., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231190941 · Cited by 86
Tauschmann, M., Cardona‐Hernandez, R., DeSalvo, D. J., Hood, K. K., Лаптев, Д. Н., Olinder, A. L., Wheeler, B. J., & Smart, C. E. (2025) · Hormone Research in Paediatrics · doi:10.1159/000543156 · Cited by 82
Eichenlaub, M., Pleus, S., Rothenbühler, M., Bailey, T. S., Bally, L., Brazg, R., Bruttomesso, D., Diem, P., Boija, E. E., Fokkert, M. J., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0465 · Cited by 55
Self-citationPemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., Taplin, C. E., Choudhary, P., & Adolfsson, P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14962 · Cited by 44
Klonoff, D. C., Gabbay, M., Moon, S. J., & Wilmot, E. G. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241250357 · Cited by 36
Metadata
- Authors
- Hochfellner, D. A., Simic, A., Taucher, M. T., Sailer, L. S., Kopanz, J., Pöttler, T., & Mader, J. K.
- Affiliations
- Medical University of Graz (AT)
- Corresponding author
- Mader, Julia K.
- Venue
- Biosensors
- Publisher
- MDPI AG
- Published
- 2022-02-09
- Volume
- 12
- Issue
- 2
- Pages
- 106
- ISSN
- 2079-6374 (ISSN-L)
- PMC
- PMC8869704
- OpenAlex
- W4221119598
- Cited by
- 15
- References
- 33
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 1
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biosensors (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Menarini (Italy) (n/a)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Physical Sciences › Chemistry › Analytical Chemistry › Electrochemical sensors and biosensors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- continuous glucose monitoring, type 1 diabetes, sensor accuracy, self-monitoring of blood glucose, mean absolute relative difference, plasma glucose, healthcare waste reduction, usability
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Humans, Pilot Projects, Technology, Blood Glucose Self-Monitoring, Reproducibility of Results
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

